These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7909494

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
    Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM.
    Cancer Res; 2001 Feb 15; 61(4):1671-7. PubMed ID: 11245482
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 8. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway.
    Yen L, Nie ZR, You XL, Richard S, Langton-Webster BC, Alaoui-Jamali MA.
    Oncogene; 1997 Apr 17; 14(15):1827-35. PubMed ID: 9150389
    [Abstract] [Full Text] [Related]

  • 9. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 17; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 10. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP, Kokeny KE, Ridings JW, Dilts CA.
    Cancer Res; 1996 Feb 15; 56(4):899-907. PubMed ID: 8631031
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 12. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC.
    Clin Cancer Res; 1998 Oct 01; 4(10):2545-50. PubMed ID: 9796989
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.
    Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG.
    J Med Chem; 1995 Sep 15; 38(19):3806-12. PubMed ID: 7562911
    [Abstract] [Full Text] [Related]

  • 15. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 15; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP.
    Mol Carcinog; 1996 Mar 15; 15(3):227-38. PubMed ID: 8597535
    [Abstract] [Full Text] [Related]

  • 17. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
    Yoon SO, Shin S, Lipscomb EA.
    Cancer Res; 2006 Mar 01; 66(5):2732-9. PubMed ID: 16510594
    [Abstract] [Full Text] [Related]

  • 18. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 19. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases.
    Sakagami M, Morrison P, Welch WJ.
    Cell Stress Chaperones; 1999 Mar 27; 4(1):19-28. PubMed ID: 10467105
    [Abstract] [Full Text] [Related]

  • 20. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
    Kumar R, Mendelsohn J.
    Anticancer Res; 1994 Mar 27; 14(3A):1001-8. PubMed ID: 7915505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.